PenderFund Capital Management Ltd.
Position in XENE — Xenon Pharmaceuticals Inc.
CIK 1706164
VANCOUVER, A1
Position in XENE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$398,327
+$91,310 QoQ
Shares Held
6,850
0.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PenderFund Capital Management Ltd. holds $2,724,879 across 7 Biotechnology names. XENE ranks #4 (14.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FOLD |
AMICUS THERAPEUTICS, INC.
|
41,100 | $594,306 | |
| 2 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
205,000 | $580,150 | |
| 3 | DAWN |
Day One Biopharmaceuticals, Inc.
|
26,800 | $574,592 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
6,850 | $398,327 | |
| 5 | ACLX |
Arcellx, Inc.
|
2,900 | $332,978 | |
| 6 | LSTA |
Lisata Therapeutics, Inc.
|
47,500 | $237,975 | |
| 7 | RNA |
Atrium Therapeutics, Inc.
|
490 | $6,551 |
All Filings in XENE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $398,327 | 6,850 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $307,017 | 6,850 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $275,027 | 6,850 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||